Results 71 to 80 of about 29,860 (191)

Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).

, 2019
Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).
Leonie Van Zyl (7512503), Elizabeth J. Ragan (5662181), Karen R. Jacobson (7512512), Tara C. Bouton (7512494), Laura F. White (7512500), Margaretha de Vos (7512497), C. Robert Horsburgh (7512506), Robin M. Warren (7512509), Danie Theron (497398)   +8 more
core   +1 more source

Bedaquiline, linezolid, pretomanid: their adverse events [PDF]

, 2020
The article discusses the clinical cases and tactics of treatment with bedaquiline, linezolid, and pretomanid in patients with multiple and extensive drug resistance.
Саргсян, В. С., Ponomarenko, A. D., Блохина, А. А., Пономаренко, А. Д., Sargsyan, V. S., Blokhina, A. A., Сабадаш, Е. В., Sabadash, E. V   +7 more
core  

Bedaquiline Effect Towards QT Interval in Drug Resistant Tuberculosis (DR-TB): A Systematic Review

Siriraj Medical Journal, 2023
Objective: Bedaquiline is recommended by World Health Organization (WHO) to treat Drug-Resistant Tuberculosis (DR-TB). Bedaquiline is chosen due to its efficacy and safety in numerous studies.
Arya Marganda Simanjuntak, Rahmadini Aulia, Dhewa Triguna Banjarnahor, Riski Dimas Harianja, Indra Yovi   +4 more
doaj  

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution.
Mairi C. W. McClean, Simon E. Koele, Julia Dreisbach, Susanne Mirold‐Mei, Fred Njeleka, Daniel Mapamba, Bariki Mtafya, Patrick P. J. Phillips, Veronique R. De Jager, Rodney Dawson, Kim Narunsky, Andreas H. Diacon, Elin M. Svensson, Norbert Heinrich, Francesco Paolo Casale, Michael Hoelscher   +15 more
wiley   +1 more source

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis

Genome Medicine
Background Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of ...
Camus Nimmo, Arturo Torres Ortiz, Cedric C. S. Tan, Juanita Pang, Mislav Acman, James Millard, Nesri Padayatchi, Alison D. Grant, Max O’Donnell, Alex Pym, Ola B. Brynildsrud, Vegard Eldholm, Louis Grandjean, Xavier Didelot, François Balloux, Lucy van Dorp   +15 more
doaj   +1 more source

QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions

Pharmacology and Clinical Pharmacy Research
Background: The cardiac safety of regimens containing bedaquiline and delamanid is not well-established, especially in Indonesia.  This study aimed to analyze QTc interval during six months of treatment and factors associated with QTc interval ...
Oki Nugraha Putra
doaj   +1 more source

Efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis: immediate and final results

Туберкулез и болезни лёгких, 2019
The objective of the study: to determine the efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis in the context of everyday clinical practice with minimal non-inclusion criteria.
S. E. Borisov, A. V. Filippov, D. A. Ivanova, T. N. Ivanushkina, N. V. Litvinova, Yu. Yu. Garmash   +5 more
doaj   +1 more source

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

EClinicalMedicine, 2020
Background: Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in ...
Erika Mohr-Holland, Anja Reuter, Jennifer Furin, Anthony Garcia-Prats, Virginia De Azevedo, Vanessa Mudaly, Yulene Kock, Laura Trivino-Duran, Petros Isaakidis, Jennifer Hughes   +9 more
doaj   +1 more source

Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors

ChemMedChem, Volume 21, Issue 14, 29 July 2026.
Following the discovery of oxadiazin‐5‐ones as partial inhibitors of the ATP synthase, we herein report the synthesis of a library of pyrazolidine‐3‐ones and pyrazol‐3‐ones, designed by reducing the six‐membered N–N heterocycles to five‐membered rings.
Lisa Reichert, Aro Delparente, Ida R. Hipfinger, Lukas Reininger, Ana Pinto Castro, Daniel J. Hubin, Roger Schibli, Amy E. Fraley, Linjing Mu   +8 more
wiley   +1 more source

Bedaquiline for the treatment of drug-resistant tuberculosis

, 2015
Bedaquiline is a much-needed novel drug which is highly effective against drug-resistant tuberculosis. While its clinical development has been laudably fast-tracked and the drug is now available for inclusion into treatment regimens when no suitable ...
Heuvelings, Charlotte C., Grobusch, Martin P., Bélard, Sabine, Janssen, Saskia   +3 more
core   +1 more source